Showing 7361-7370 of 8649 results for "".
- 'Love Your Eyes' Confirmed as the Theme for World Sight Day 2022https://modernod.com/news/love-your-eyes-confirmed-as-the-theme-for-world-sight-day-2022/2480763/The International Agency for the Prevention of Blindness (IAPB) has confirmed it will continue the theme of #LoveYourEyes for World Sight Day 2022. World Sight Day 2021 saw over 3.5 million eye test pledges made by individuals, eye care professionals, hospitals, NGOs and businesses. Thi
- Bruder Introduces In-Office Package Options for Moist Heat Eye Compresshttps://modernod.com/news/bruder-introduces-in-office-package-options-for-moist-heat-eye-compress/2480759/Bruder recently introduced two new in-office package options for its moist heat eye compress. A new box and counter display make retail opportunities easier by offering an attractive, small-footprint way to showcase the Bruder Eye Compress in high-traffic, point-of sale locations throughout
- Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucomahttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma/2480758/Nicox announced that the results from its Dolomites phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma. The publication “A R
- Researchers Generate First Complete, Gapless Sequence of a Human Genomehttps://modernod.com/news/researchers-generate-first-complete-gapless-sequence-of-a-human-genome/2480741/Scientists have published the first complete, gapless sequence of a human genome, two decades after the Human Genome Project produced the first draft human genome sequence, according to the National Institutes of Health. According to researchers, having a complete, gap-free sequen
- Study: Dry Eye Disease Signs and Symptoms Significantly Reduced with Ciclosporin A 0.1% Cationic Emulsionhttps://modernod.com/news/study-dry-eye-disease-signs-and-symptoms-significantly-reduced-with-ciclosporin-a-01-cationic-emulsion/2480734/Santen EMEA has announced the results of PERSPECTIVE, a real-world evidence study evaluating the long-term treatment of severe keratitis in adult dry eye disease (DED) patients. The study, which was conducted across 44 ophthalmology clinics in 5 European countries, demonstrated that ciclosporin A
- Graybug Updates its Ophthalmic Pipeline Programshttps://modernod.com/news/graybug-updates-its-ophthalmic-pipeline-programs/2480733/Graybug Vision announced a strategic update on its pipeline programs GB-102 in wet age-related macular degeneration (AMD); GB-401, in primary open-angle glaucoma (POAG); as well as its newly acquired assets in corneal disease (GB-501); inherited retinal diseases (GB-601); and
- Icare USA Introduces iCare HOME2 Self-Tonometerhttps://modernod.com/news/icare-usa-introduces-icare-home2-self-tonometer/2480731/Icare USA annou
- Ocuphire Meets Endpoints in Phase 3 MIRA-3 Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-mira-3-phase-3-fda-registration-trial-for-nyxol-in-the-reversal-of-mydriasis/2480730/Ocuphire Pharma announced positive topline results in the MIRA-3 trial, the company’s second phase 3 registration trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). Ocuphire announced positive results from i
- Innovega Grants Commercial License of its Next-Generation Display Eyewear to Global Supplierhttps://modernod.com/news/innovega-grants-commercial-license-of-its-next-generation-display-eyewear-to-global-supplier/2480728/Innovega finalized a definitive licensing agreement with one of the world's leading providers of assistive technology for the visually impaired, including the legally blind. This is the first commercial licensing agreement for Innovega’s next-generation display eyewear
- Penn Researchers Develop Gene Therapy that Restores Dim-Light Vision in Dogshttps://modernod.com/news/penn-researchers-develop-gene-therapy-that-restores-dim-light-vision-in-dogs/2480723/In the journal Proceedings of the National Academy of Sciences, University of Pennsylvania researchers reported a major advance: a gene therapy that returns night vision to dogs born with congenital stationary night blindness